Sage Therapeutics SAGE 深 沪
等待开盘 07-08 09:30:00 美东时间
8.68
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 8.68
- 总市值 5.44亿
- 52周最高 9.36
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 4.62
- 委 比 0.00%
- 总股本 6262.23万
- 历史最高 195.97
- 量 比 0
- 振 幅 0.00%
- 历史最低 4.62
- 每 手 1
- 风险率 0.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Dyne Therapeutics Appoints Barry Greene to Board of Directors
Dyne Therapeutics announced the appointment of Barry Greene to its Board of Directors. With over three decades of experience in the biopharmaceutical industry, Greene brings a proven track record of building and scaling innovative companies across rare diseases, neuroscience, and oncology. His leadership includes roles at Sage Therapeutics and Alnylam Pharmaceuticals, where he contributed to the development and commercialization of novel therapie...
06-22 20:10
UPDATE 2-Definium's LSD-based depression pill delivers strong late-stage results, shares surge
UPDATE 2-Definium's LSD-based depression pill delivers strong late-stage results, shares surge Updates share movement, adds analyst comment 6 and 7, background throughout By Kamal Choudhury June 22 (Reuters) - Definium Therapeutics DFTX.O said a single dose of its LSD-based experimental pill signifi
06-22 19:11
Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
Relmada Therapeutics appoints Michael Quirk, PhD, as Senior Advisor for its sepranolone program. With over 20 years of experience in CNS drug discovery, Quirk previously served as Chief Scientific Officer at Sage Therapeutics. Sepranolone, a GABA_A receptor modulator, targets Prader-Willi Syndrome and other CNS disorders by selectively antagonizing allopregnanolone without disrupting GABAergic signaling. Quirk emphasizes sepranolone's potential a...
06-11 11:00
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
Entera Bio Ltd. reported Q1 2026 financial results and business updates, highlighting progress in its oral peptide therapeutics pipeline. Key developments include the submission of a streamlined Phase 3 protocol for EB613, an oral anabolic tablet for postmenopausal osteoporosis, and expanded collaboration with OPKO for EB612, an oral long-acting PTH tablet for hypoparathyroidism. Additionally, data for EB618, an oral dual GLP-1/glucagon tablet fo...
05-08 20:05
Harmony Biosciences Announces The Appointment Of Peter Anastasiou As Chief Operating Officer
Appointments support Harmony's next phase of growth and long‑term value creationHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the appointment of Peter Anastasiou as Chief Operating Officer and updates
04-02 20:11
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones
Entera Bio Ltd. has appointed Geno J. Germano as its new Chairman, succeeding Gerald Lieberman. Germano, with over three decades of leadership experience in the biopharmaceutical industry, including senior roles at Pfizer and Wyeth, will guide Entera during a pivotal phase as the company advances two oral peptide programs into clinical trials in 2026: a Phase 3 study for EB613 in osteoporosis and a first-in-human study for Long-Acting Oral PTH in...
02-09 13:50
Biogen projects 2026 revenue drop despite Q4 beat
Despite recording better-than-expected Q4 2025 financials, Biogen (BIIB) on Friday projected a mid-single-digit percentage decline in revenue for 2026 compared to last year amid pressure on its multip...
02-06 20:02
Supernus Pharma Q3 revenue rises, partly helped by Sage acquisition
Overview Supernus Q3 2025 total rev rises 9% yr/yr, driven by growth products Company completed acquisition of Sage Therapeutics, contributing to collaboration revenue Operating loss in Q3 due to acqu...
2025-11-05 05:34
Supernus Pharmaceuticals reports third quarter revenue of $192.1 million
Supernus Pharmaceuticals Inc. reported total revenues of $192.1 million for the third quarter of 2025, a 9% increase compared to the same period in 2024. Combined revenues from the company's four grow...
2025-11-05 05:01
Supernus Pharmaceuticals Q2 revenue falls
Overview Supernus Q2 2025 total revenue dips 2% yr/yr to $165.5 mln Adjusted revenue excluding Trokendi XR, Oxtellar XR rises 17% yr/yr Co completes Sage Therapeutics acquisition, enhancing neuropsych...
2025-08-06 05:33
